Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Nov;33(11):1908–1914. doi: 10.1128/aac.33.11.1908

Toxicity and efficacy of 2',3'-dideoxycytidine in clinical trials of pigtailed macaques infected with simian retrovirus type 2.

C C Tsai 1, K E Follis 1, M Yarnall 1, G A Blakley 1
PMCID: PMC172786  PMID: 2558613

Abstract

Four dosing regimens of 2',3'-dideoxycytidine (ddC) were administered intravenously for 10 to 28 days to 18 pigtailed macaques with simian acquired immunodeficiency syndrome. Ten macaques naturally infected with simian acquired immunodeficiency syndrome retrovirus serotype 2 (SRV-2), the etiologic agent of simian acquired immunodeficiency syndrome, received ddC by continuous intravenous infusion or by a daily bolus injection for 10 to 12 days. Another eight macaques that were negative for SRV-2 and antibody received ddC prophylaxis prior to challenge with virus and continued to receive ddC therapy for up to 28 days postchallenge. All monkeys treated with a continuous intravenous dose of ddC, which maintained plasma concentrations of ddC at levels known to inhibit SRV-2 in vitro, developed dose-related toxic effects, including leukopenia, anemia, lethargy, and decreased appetite. Monkeys treated with a daily bolus injection of ddC experienced more severe toxic effects than those on the continuous intravenous regimen, including exfoliative dermatitis and peripheral neuropathy. At the concentrations of ddC administered, no significant inhibition of SRV-2 replication was detected in naturally infected macaques. However, a prophylactic regimen of ddC did have an inhibitory effect on SRV-2. Our findings suggest that ddC may be valuable as a short-term prophylactic treatment rather than as a long-term therapy.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DaRif C. A., Rush H. G. Management of septicemia in rhesus monkeys with chronic indwelling venous catheters. Lab Anim Sci. 1983 Feb;33(1):90–94. [PubMed] [Google Scholar]
  2. Daniel M. D., King N. W., Letvin N. L., Hunt R. D., Sehgal P. K., Desrosiers R. C. A new type D retrovirus isolated from macaques with an immunodeficiency syndrome. Science. 1984 Feb 10;223(4636):602–605. doi: 10.1126/science.6695172. [DOI] [PubMed] [Google Scholar]
  3. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  4. Gardner M. B., Luciw P., Lerche N., Marx P. Nonhuman primate retrovirus isolates and AIDS. Adv Vet Sci Comp Med. 1988;32:171–226. doi: 10.1016/b978-0-12-039232-2.50011-6. [DOI] [PubMed] [Google Scholar]
  5. Jacobson M. A., Gellermann H., Chambers H. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. Am J Med. 1988 Aug;85(2):172–176. doi: 10.1016/s0002-9343(88)80337-1. [DOI] [PubMed] [Google Scholar]
  6. Kalin J. R., Hill D. L. Determination of 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine and 2',3'-dideoxycytidine in biological samples. J Chromatogr. 1988 Sep 23;431(1):184–191. doi: 10.1016/s0378-4347(00)83083-2. [DOI] [PubMed] [Google Scholar]
  7. Kelley J. A., Litterst C. L., Roth J. S., Vistica D. T., Poplack D. G., Cooney D. A., Nadkarni M., Balis F. M., Broder S., Johns D. G. The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab Dispos. 1987 Sep-Oct;15(5):595–601. [PubMed] [Google Scholar]
  8. Lackner A. A., Rodriguez M. H., Bush C. E., Munn R. J., Kwang H. S., Moore P. F., Osborn K. G., Marx P. A., Gardner M. B., Lowenstine L. J. Distribution of a macaque immunosuppressive type D retrovirus in neural, lymphoid, and salivary tissues. J Virol. 1988 Jun;62(6):2134–2142. doi: 10.1128/jvi.62.6.2134-2142.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. MacKenzie M., Lowenstine L., Lalchandani R., Lerche N., Osborn K., Spinner A., Bleviss M., Hendrickson R., Gardner M. Hematologic abnormalities in simian acquired immune deficiency syndrome. Lab Anim Sci. 1986 Feb;36(1):14–19. [PubMed] [Google Scholar]
  10. Maul D. H., Zaiss C. P., MacKenzie M. R., Shiigi S. M., Marx P. A., Gardner M. B. Simian retrovirus D serogroup 1 has a broad cellular tropism for lymphoid and nonlymphoid cells. J Virol. 1988 May;62(5):1768–1773. doi: 10.1128/jvi.62.5.1768-1773.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Meyer P. R., Ormerod L. D., Osborn K. G., Lowenstine L. J., Hendrickson R. V., Modlin R. L., Smith R. E., Gardner M. B., Taylor C. R. An immunopathologic evaluation of lymph nodes from monkey and man with acquired immune deficiency syndrome and related conditions. Hematol Oncol. 1985 Jul-Sep;3(3):199–210. doi: 10.1002/hon.2900030308. [DOI] [PubMed] [Google Scholar]
  12. Morton W. R., Knitter G. H., Smith P. M., Susor T. G., Schmitt K. Alternatives to chronic restraint of nonhuman primates. J Am Vet Med Assoc. 1987 Nov 15;191(10):1282–1286. [PubMed] [Google Scholar]
  13. Osborn K. G., Prahalada S., Lowenstine L. J., Gardner M. B., Maul D. H., Henrickson R. V. The pathology of an epizootic of acquired immunodeficiency in rhesus macaques. Am J Pathol. 1984 Jan;114(1):94–103. [PMC free article] [PubMed] [Google Scholar]
  14. Pizzo P. A., Eddy J., Falloon J., Balis F. M., Murphy R. F., Moss H., Wolters P., Brouwers P., Jarosinski P., Rubin M. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988 Oct 6;319(14):889–896. doi: 10.1056/NEJM198810063191401. [DOI] [PubMed] [Google Scholar]
  15. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  16. Sadoff D. A., Giddens W. E., Jr, Morton W. R. Cerebellar cortical atrophy in a baboon. Vet Pathol. 1986 May;23(3):335–336. doi: 10.1177/030098588602300319. [DOI] [PubMed] [Google Scholar]
  17. Spector S. A., Ripley D., Hsia K. Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone. Antimicrob Agents Chemother. 1989 Jun;33(6):920–923. doi: 10.1128/aac.33.6.920. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Stromberg K., Benveniste R. E., Arthur L. O., Rabin H., Giddens W. E., Jr, Ochs H. D., Morton W. R., Tsai C. C. Characterization of exogenous type D retrovirus from a fibroma of a macaque with simian AIDS and fibromatosis. Science. 1984 Apr 20;224(4646):289–282. doi: 10.1126/science.6200929. [DOI] [PubMed] [Google Scholar]
  19. Tsai C. C., Follis K. E., Benveniste R. E. Antiviral effects of 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, and 2',3'-dideoxyadenosine against simian acquired immunodeficiency syndrome-associated type D retrovirus in vitro. AIDS Res Hum Retroviruses. 1988 Oct;4(5):359–368. doi: 10.1089/aid.1988.4.359. [DOI] [PubMed] [Google Scholar]
  20. Tsai C. C., Giddens W. E., Jr, Morton W. R., Rosenkranz S. L., Ochs H. D., Benveniste R. E. Retroperitoneal fibromatosis and acquired immunodeficiency syndrome in macaques: epidemiologic studies. Lab Anim Sci. 1985 Oct;35(5):460–464. [PubMed] [Google Scholar]
  21. Tsai C. C., Giddens W. E., Jr, Ochs H. D., Morton W. R., Knitter G. H., Blakley G. A., Benveniste R. E. Retroperitoneal fibromatosis and acquired immunodeficiency syndrome in macaques: clinical and immunologic studies. Lab Anim Sci. 1986 Apr;36(2):119–125. [PubMed] [Google Scholar]
  22. Yarchoan R., Broder S. Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med. 1987 Feb 26;316(9):557–564. doi: 10.1056/NEJM198702263160925. [DOI] [PubMed] [Google Scholar]
  23. Yarchoan R., Perno C. F., Thomas R. V., Klecker R. W., Allain J. P., Wills R. J., McAtee N., Fischl M. A., Dubinsky R., McNeely M. C. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988 Jan 16;1(8577):76–81. doi: 10.1016/s0140-6736(88)90283-8. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES